                             UNITED STATES DISTRICT COURT
                             FOR THE DISTRICT OF COLUMBIA

ORGANOGENESIS INC.,                                 :
                                                    :
        Plaintiff,                                  :       Civil Action No.:       13-cv-2033 (RC)
                                                    :
        v.                                          :       Re Document No.:        3, 12
                                                    :
KATHLEEN SEBELIUS,                                  :
                                                    :
        Defendant.                                  :

                                   MEMORANDUM OPINION

  GRANTING DEFENDANT’S MOTION TO DISMISS AND DENYING PLAINTIFF’S MOTION FOR A
                       PRELIMINARY INJUNCTION AS MOOT

                                        I. INTRODUCTION

        Plaintiff, Organogenesis, has filed suit against Defendant Kathleen Sebelius, in her

official capacity as Secretary of Health and Human Services (“HHS”), challenging under the

Administrative Procedures Act (“APA”) the Centers for Medicare & Medicaid Services’s

(“CMS”) 2014 final rule packaging the drug Apligraf into payment for the service in which it is

applied. Presently before the Court is Plaintiff’s motion for preliminary injunction and

Defendant’s motion to dismiss. Upon consideration of the pleadings and the relevant legal

authorities, the Court finds that it lacks jurisdiction to resolve the merits of the Plaintiff’s claims.

Accordingly, the Court grants Defendant’s motion to dismiss and denies Plaintiff’s motion for a

preliminary injunction as moot. The Court shall not address Plaintiff’s motion for a preliminary

injunction in its Memorandum Opinion, but only the Defendant’s motion to dismiss.
                                II. FACTUAL BACKGROUND

       Title XVIII of the Social Security Act of 1935, 42 U.S.C. §1395 et seq., establishes the

Medicare program, which provides federally funded medical insurance to the elderly and

disabled. Part A of the Medicare program provides insurance coverage for inpatient hospital

care, home health care, and hospice services. Id. §1395c. Part B of Medicare is a voluntary

program that provides supplemental coverage for other types of care, including outpatient

hospital care. Id. §§ 1395j, 1395k. Under this program, physicians, hospitals, and other health

care providers may obtain payment from Medicare when they provide covered services to

persons enrolled in Medicare Part B. The Medicare program is subject to both fiscal limits and

restrictions on administrative and judicial review.

       A component of the Medicare Part B program is the Outpatient Prospective Payment

System (“OPPS”), which pays hospitals directly to provide outpatient services to beneficiaries.

Under OPPS, hospitals are paid prospectively for their services in each upcoming year, thus

requiring payments for outpatient hospital care to be made based on predetermined rates. See

Balanced Budget Act of 1997, Pub. L. No. 105-33, 111 Stat. 251 (1997). Under OPPS, payment

is based on the Ambulatory Payment Classification (“APC”) to which an item or service is

assigned. Pursuant to 42 U.S.C. §1395l(t), payments are calculated through a formula, setting

payment weights for the provision of certain services, or groups of clinically similar services, as

determined by the agency. Id. at §§1395l(t)(2)(C). These APC calculations are based on the

mean or median cost of providing such services in past years, with adjustments for regional cost

variations. Id. at §§1395l(t)(2)(C) – (D). Hospitals facing actual costs significantly above their

prospective payment amounts receive outlier adjustments from the Secretary of the Department

of Health and Human Services. Id. §1395l(t)(2)(E). Hospitals can also receive supplemental




                                                 2
payments, called “pass-through” payments, to help cover the cost of providing certain

treatments, including new drugs, biologicals, and medical devices. Id. §1395l(t)(6).

       The Balanced Budget Refinement Act of 1999 required CMS to annually update payment

weights, relative payment rates, wage adjustments, outlier payments, and APC groups. It also

required CMS to establish payments in a “budget-neutral” manner — that is, CMS must maintain

a balanced budget and cannot provide payments exceeding a set budget. Id. §1395l(t)(2)(E).

Thus, whenever the Secretary makes any type of payment adjustment, the additional projected

expenses must be offset by a reduction in all prospective payment rates. Id.

       Apart from reimbursement authority for general outpatient services, CMS must

separately pay for a category of drugs and biologicals known as “specified covered outpatient

drugs” (“SCODs”). The Medicare Prescription Drug, Improvement, and Modernization Act of

2003 (“MMA”) Pub. L. No. 108-173, §621(a), 117 Stat. 2066, 2307 (2003). Congress has

specified the methodology for determining the payment rates of SCODs in a separate provision.

See 42 U.S.C. §1395l(t)(14). This provision defines a SCOD as follows:

       In this paragraph, the term “specified covered outpatient drug” means, subject to
       clause (ii), a covered outpatient drug (as defined in section 1396r-8(k)(2) of this
       title) for which a separate ambulatory classification group (APC) has been
       established and that is--

       (I)     a radiopharmaceutical; or

       (II)    a drug or biological for which payment was made under paragraph (6)
               (relating to pass-through payments) on or before December 31, 2002.

Covered outpatient drug is defined in 42 U.S.C. §1396r-8(k)(2) as follows:

       Subject to the exceptions in paragraph (3), the term “covered outpatient drug”
       means –

       (A) of those drugs which are treated as prescribed drugs for purposes of section
       1396d(a)(12) of this title, a drug which may be dispensed only upon prescription
       (except as provided in paragraph (5)), and—



                                                3
              (i) which is approved for safety and effectiveness as a prescription drug
              under section 505 or 507 of the Federal Food, Drug, and Cosmetic Act [21
              U.S.C.A. § 355 or 357] or which is approved under section 505(j) of such
              Act [21 U.S.C.A. § 355(j) ];

              (ii) (I) which was commercially used or sold in the United States before
              October 10, 1962, or which is identical, similar, or related (within the
              meaning of section 310.6(b)(1) of title 21 of the Code of Federal
              Regulations) to such a drug; and (II) which has not been the subject of a
              final determination by the Secretary that it is a “new drug” (within the
              meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act
              [21 U.S.C.A. § 321(p)]) or an action brought by the Secretary under
              section 301, 302(a), or 304(a) of such Act [21 U.S.C.A. § 331, 332(a), or
              334(a) ] to enforce section 502(f) or 505(a) of such Act [21 U.S.C.A. §
              352(f) or 355(a) ]; or

              (iii) (I) which is described in section 107(c)(3) of the Drug Amendments
              of 1962 and for which the Secretary has determined there is a compelling
              justification for its medical need, or is identical, similar, or related (within
              the meaning of section 310.6(b)(1) of title 21 of the Code of Federal
              Regulations) to such a drug, and (II) for which the Secretary has not issued
              a notice of an opportunity for a hearing under section 505(e) of the Federal
              Food, Drug, and Cosmetic Act [21 U.S.C.A. § 355(e) ] on a proposed
              order of the Secretary to withdraw approval of an application for such
              drug under such section because the Secretary has determined that the
              drug is less than effective for some or all conditions of use prescribed,
              recommended, or suggested in its labeling; and

       (B) a biological product, other than a vaccine which—

              (i) may only be dispensed upon prescription,

              (ii) is licensed under section 262 of this title, and

              (iii) is produced at an establishment licensed under such section to
              produce such product; and

       (C) insulin certified under section 506 of the Federal Food, Drug, and Cosmetic
       Act [21 U.S.C.A. § 356].

       In 2004 and 2005, CMS was required to provide separate reimbursement for SCODs, as

determined by Congress’s payment methodology laid forth in the MMA. 42 U.S.C.

§1395l(t)(14)(A)(i)-(ii). During these years, CMS also provided separate reimbursement for

other high-cost drugs and biologicals that were not SCODs, but based payment on a different



                                                 4
methodology — the median cost methodology that CMS also applied to non-drug items and

services. 69 Fed. Red. 65,682, 65,800 (Nov. 15, 2004). Starting in 2006, however, CMS began

to use the SCOD methodology to calculate payments for non-SCOD, high-cost drugs and

biologicals. CMS recognized that it was required by statute to pay for SCODs based on the

specific payment methodology established in the MMA, but decided to extend that methodology

to non-SCOD drugs and biologicals as a policy choice. 77 Fed. Reg. 68,210, 68,383 (Nov. 15,

2012).

         Apligraf is a bioengineered product manufactured from living skin cells. It is made from

living healthy cells that stimulate a wound to heal. It is used in the treatment of chronic, hard-to-

heal venous leg ulcers and diabetic foot ulcers. In 1998, the FDA approved Apligraf for

marketing under its premarket approval (“PMA”) process for “use with standard therapeutic

compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous

insufficiency of greater than adequately responded to conventional ulcer therapy.” FDA CDRH,

Summary of Safety and Effectiveness Data: Apligraf, Available at:

http://www.accessdata.fda.gov/cdrh_docs/pdf/P950032b.pdf. In 2001, CMS granted Apligraf

pass-through status as a biological pursuant to 42 U.S.C. §1395l(t)(6). Although Apligraf was

originally approved under a PMA, Organogenesis asserts that it has been informed by the Center

for Biologics at the FDA that all new clinical indications for Apligraf will be approved through

the Biologic License Application (“BLA”) pathway. See Pl.’s Mot. for Preliminary Injunction,

15, Dec. 20, 2013, ECF No. 3.

         On July 19, 2013, by notice of proposed rulemaking in the Federal Register, CMS

proposed to begin packaging together a category known as “skin substitutes,” which included

Apligraf, with their associated surgical procedures. See 78 Fed. Reg. 43534, 43571. CMS issued




                                                  5
the final rule on December 10, 2013. 78 Fed. Reg. 74826, 74930 (Dec. 10, 2013). The Final Rule

further divides “skin substitute” products into high-cost and low-cost categories, and provides

different payment rates for each group. Id. Apligraf is assigned to the high-cost category. Id. By

packaging Apligraf with its corresponding surgical procedure, instead of reimbursing for

Apligraf separately using the SCOD methodology, Organogenesis claims that outpatient hospital

reimbursement for Apligraf has been reduced by $730 per unit, and ambulatory surgical center

reimbursement has been reduced by $1,215 per unit. Pl.’s Mot. for Preliminary Injunction, 10-

11.

        Plaintiff argues that this Final Rule improperly groups and reimburses for Apligraf as a

part of a procedure package, instead of paying for Apligraf separately as a SCOD. Plaintiff

believes that Apligraf is properly a SCOD, and thus should be reimbursed separately using the

Congressionally prescribed SCOD methodology. Plaintiff seeks a preliminary injunction of the

CMS’s final rule. Defendant has filed a motion to dismiss Plaintiff’s complaint for lack of

jurisdiction.




                                    III. LEGAL STANDARD

                A. Motion to Dismiss for Lack of Subject Matter Jurisdiction

        A motion to dismiss under Federal Rule of Civil Procedure 12(b)(1) “presents a threshold

challenge to the Court’s jurisdiction,” and thus “the Court is obligated to determine whether it

has subject-matter jurisdiction in the first instance.” Curran v. Holder, 626 F. Supp. 2d 30, 32

(D.D.C. 2009) (internal citation and quotation marks omitted). “[I]t is presumed that a cause lies

outside [the federal courts’] limited jurisdiction, and the burden establishing the contrary rests

upon the party asserting jurisdiction.” Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375,


                                                  6
377 (1994); United States ex rel. Digital Healthcare, Inc. v. Affiliated Computer, 778 F. Supp. 2d

37, 43 (D.D.C. 2011) (citing Hollingsworth v. Duff, 444 F. Supp. 2d 61, 63 (D.D.C. 2006)).

        Jurisdiction must be established in each type of case brought before the Court, including

challenges to an agency action. Indeed, while the “APA generally establishes a cause of action

for those suffering legal wrong because of agency action, or adversely affected or aggrieved by

agency action,” the “APA does not apply, however, to the extent that … statutes preclude

judicial review.” Texas Alliance for Home Care Services v. Sebelius, 681 F.3d 402, 408 (D.C.

Cir. 2012) (internal quotations omitted); 5 U.S.C. §701(a)(1) (stating that the judicial review

provisions of the Administrative Procedure Act are inapplicable to the extent that “statutes

preclude judicial review”). However, to determine “[w]hether and to what extent a particular

statute precludes judicial review,” a Court must look to the statute’s “express language…the

structure of the statutory schemes, its objectives, its legislative history, and the nature of the

administrative action involved.” Block v. Community Nutrition Inst., 467 U.S. 340, 345 (1984).

The presumption is in favor of permitting review of administrative action, but that presumption

can be overcome where “congressional intent to preclude judicial review is ‘fairly discernible in

the statutory scheme.’” Id. at 351 (quoting Ass’n of Data Processing Service Organizations v.

Camp, 397 U.S. 150, 157 (1970)).


                                          IV. ANALYSIS

        Defendant has moved to dismiss Plaintiff’s complaint, arguing that this Court lacks

jurisdiction to entertain Plaintiff’s claim because: 1) adjustments to OPPS funding decisions are

not subject to judicial review, pursuant to 42 U.S.C. §1395l(t)(12)(A), and 2) the administrative

remedies available under the Medicare Statute were not first pursued. The Court finds that it




                                                   7
lacks jurisdiction to hear Plaintiff’s claims pursuant to 42 U.S.C. §1395l(t)(12)(A), and thus does

not reach Defendant’s second argument.

       To determine “[w]hether and to what extent a particular statute precludes judicial

review,” a Court must look to the statute’s “express language…the structure of the statutory

schemes, its objectives, its legislative history, and the nature of the administrative action

involved.” Block v. Community Nutrition Inst., 467 U.S. 340, 345 (1984). Nonetheless, the “first

step in interpreting a statute is to determine whether the language at issue has a plain and

unambiguous meaning with regard to the particular dispute in the case. Our inquiry must cease if

the statutory language is unambiguous and ‘the statutory scheme is coherent and consistent.’ ”

Robinson v. Shell Oil Co., 519 U.S. 337, 340 (1997) (quoting United States v. Ron Pair

Enterprises, Inc., 489 U.S. 235, 240 (1989)).

       42 U.S.C. §1395l(t)(12)(A) states that “there shall be no…judicial review…of this title or

of the development of the classification system…including the establishment of groups and

relative payment weights for covered OPD [Out Patient Department] services.” The D.C. Circuit

has previously interpreted this provision to “clearly preclude judicial review of the Secretary’s

adjustments to prospective payment amounts.” Amgen, Inc. v. Smith, 357 F.3d 103, 112 (D.C.

Cir. 2004). Moreover, the D.C. Circuit found that the legislative history comports with a

preclusion of judicial review of CMS’s authority to set prospective payment methodologies.

“That Congress would use such language of prohibition is unsurprising, for piecemeal review of

individual payment determinations could frustrate the efficient operation of the complex

prospective payment system.” Id. CMS argues that it has the authority to re-classify and

repackage Apligraf with other skin substitute products pursuant to its broad powers to establish

groups under 42 U.S.C. §1395l(t)(2).




                                                  8
       Plaintiff agrees that if Apligraf is properly considered a regular OPD service under

§(t)(2), then CMS was appropriately acting pursuant to its broad authority to “establish groups”

under §(t)(2), and thus §(t)(12)(A) does in fact preclude this Court’s review of the matter.

However, Plaintiff argues that Apligraf is not a regular OPD service, and instead should properly

be considered a SCOD under 42 U.S.C. §1395l(t)(14), for which Congress has required a

separate, unpackaged payment mechanism. By grouping Apligraf payments with its surgical

procedure, Plaintiff asserts that CMS acted contrary to Congress’s mandate, and outside its

statutory authority, thus providing an “exception to the general statutory bar” of judicial review

in such cases. Pl.’s Reply in support of Preliminary Injunction, 3, Jan. 27, 2014, ECF No. 15; see

also Amgen, Inc. v. Smith, 357 F.3d 103, 112 (D.C. Cir. 2004) (construing §(t)(12) to “prevent

review only of those ‘other adjustments’ that the Medicare Act authorizes the Secretary to

make”); Texas Alliance for Home Care Servs. v. Sebelius, 811 F. Supp. 2d 76, 94 (D.D.C. 2011)

(“exception” to the jurisdictional bar where the agency acts ultra vires).

       Indeed, the only question this Court must decide is whether Apligraf properly qualifies as

a SCOD pursuant to 42 U.S.C. §1395l(t)(14) and 42 U.S.C. §1396r-8(k)(2). That is because if

Apligraf qualifies as a SCOD, this Court may hear the case under the ultra vires doctrine of

review, Def.’s Reply in support of Mot. to Dismiss, 2, Feb. 6, 2014, ECF No. 17, and that if

Apligraf does not qualify as a SCOD, 42 U.S.C. §1395l(t)(12)(A) precludes this Court’s review.

Pl.’s Reply at 3. Def.’s Reply in support of Mot. to Dismiss, 2. When “the determination of

whether the court has jurisdiction is intertwined with the question of whether the agency has

authority for the challenged action…the court must address the merits to the extent necessary to

determine whether the challenged agency action falls within the scope of the preclusion on

judicial review.” Amgen, Inc., 357 F.3d at 98.




                                                 9
       The Court thus turns to the statutory language of the relevant definitional provisions. 42

U.S.C. §1395l(t)(14) defines a SCOD as follows:

       In this paragraph, the term “specified covered outpatient drug” means, subject to
       clause (ii), a covered outpatient drug (as defined in section 1396r-8(k)(2) of this
       title) for which a separate ambulatory classification group (APC) has been
       established and that is--

       (III)   a radiopharmaceutical; or

       (IV)    a drug or biological for which payment was made under paragraph (6)
               (relating to pass-through payments) on or before December 31, 2002.

According to the plain language of this provision, a SCOD must first meet the definition of a

“covered outpatient drug.” Covered outpatient drug is defined as follows:

       Subject to the exceptions in paragraph (3), the term “covered outpatient drug”
       means –

       (A) of those drugs which are treated as prescribed drugs for purposes of section
       1396d(a)(12) of this title, a drug which may be dispensed only upon prescription
       (except as provided in paragraph (5)), and—

               (i) which is approved for safety and effectiveness as a prescription drug
               under section 505 or 507 of the Federal Food, Drug, and Cosmetic Act [21
               U.S.C.A. § 355 or 357] or which is approved under section 505(j) of such
               Act [21 U.S.C.A. § 355(j) ];

               (ii) (I) which was commercially used or sold in the United States before
               October 10, 1962, or which is identical, similar, or related (within the
               meaning of section 310.6(b)(1) of title 21 of the Code of Federal
               Regulations) to such a drug; and (II) which has not been the subject of a
               final determination by the Secretary that it is a “new drug” (within the
               meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act
               [21 U.S.C.A. § 321(p)]) or an action brought by the Secretary under
               section 301, 302(a), or 304(a) of such Act [21 U.S.C.A. § 331, 332(a), or
               334(a) ] to enforce section 502(f) or 505(a) of such Act [21 U.S.C.A. §
               352(f) or 355(a) ]; or

               (iii) (I) which is described in section 107(c)(3) of the Drug Amendments
               of 1962 and for which the Secretary has determined there is a compelling
               justification for its medical need, or is identical, similar, or related (within
               the meaning of section 310.6(b)(1) of title 21 of the Code of Federal
               Regulations) to such a drug, and (II) for which the Secretary has not issued
               a notice of an opportunity for a hearing under section 505(e) of the Federal



                                                 10
               Food, Drug, and Cosmetic Act [21 U.S.C.A. § 355(e) ] on a proposed
               order of the Secretary to withdraw approval of an application for such
               drug under such section because the Secretary has determined that the
               drug is less than effective for some or all conditions of use prescribed,
               recommended, or suggested in its labeling; and

       (B) a biological product, other than a vaccine which—

               (i) may only be dispensed upon prescription,

               (ii) is licensed under section 262 of this title, and

               (iii) is produced at an establishment licensed under such section to
               produce such product; and

       (C) insulin certified under section 506 of the Federal Food, Drug, and Cosmetic
       Act [21 U.S.C.A. § 356].

Defendant argues that Apligraf does not meet the definition of a covered outpatient drug because

“it is not approved under section 505, 507, or 505(j) of the Federal Food, Drug, and Cosmetic

Act….[n]or was Apligraf commercially used or sold in the United States before the date of the

enactment of the Drug Amendments of 1962….[n]or is Apligraf a biologic product licensed

under section [262] of the Public Health Service Act.” Def.’s Mot. to Dismiss, 15. “Finally,

Apligraf is not an insulin.” Id.

       Plaintiff does not dispute that Apligraf does not meet the definition of a covered

outpatient drug on its face. Indeed, Plaintiff acknowledges that 42 U.S.C. §1396r-8(k)(2) makes

“explicit reference only to drug and biological approval pathways” but that Apligraf was

“approved by the FDA under a device approval pathway.” Pl.’s Reply in Support of Preliminary

Injunction, 4. However, Plaintiff argues that Apligraf was approved as a device approval

pathway “due only to a historical fluke present at the time in the regulations,” and that Apligraf

is indeed the same kind of biological that would be approved under the biological license

pathway today. Pl.’s Reply, 5. In fact, Plaintiff asserts that if it were to seek new FDA approval




                                                  11
for Apligraf today, “it would be required to file a biologic license application, which is one of the

pathways specifically identified in the SCOD definition.” Id.

       Unfortunately for Plaintiff, even if Apligraf’s approval category was due to a historical

fluke, Apligraf simply does not meet the plain statutory terms of a covered outpatient drug.

Although “a reviewing court should not confine itself to examining the meaning or ambiguity of

certain words or phrases” without looking to their context, Nat’l Ass’n of Home Builders v.

Defenders of Wildlife, 551 U.S. 644, 666 (2007), “[o]ur inquiry must cease if the statutory

language is unambiguous and ‘the statutory scheme is coherent and consistent.’” Robinson, 519

U.S. at 340. And Plaintiff has not identified a single ambiguous term in the statute. Indeed,

Plaintiff appears to concede that it does not meet the explicit terms of the statute, and instead

asks the Court to read in an exception to the definition. However, when the statute is

unambiguous, the “statutory language is generally enforced as written and may be departed from

only on ‘the most extraordinary showing of contrary intentions in the legislative history.’”

Hennepin Cnty. v. Fed. Nat. Mortgage Ass'n, 742 F.3d 818, 821 (8th Cir. 2014) (citing United

States v. Sabri, 326 F.3d 937, 943 (8th Cir.2003)).

       Plaintiff does not point to such contrary legislative intent here. At best, Plaintiff argues

that, despite the statutory language, Apligraf should be treated as a SCOD under the statute

because CMS reimbursed Apligraf as a SCOD since 2004 — “a time when CMS treated as

SCODs only those products it viewed to be SCODs under the statute.” Pl.’s Reply at 6. Plaintiff

thus argues that CMS’s previous determination should be given precedential value.1



   1
      Plaintiff also seems to argue that Congress has, by its failure to revise or repeal the agency’s
interpretation, implicitly approved of CMS’s decision to treat Apligraf as a statutory SCOD.
However, CMS has never issued a rule or interpretation of the statute in which it explicitly states
that Apligraf is a statutory SCOD. Additionally, because CMS has treated non-SCOD drugs as
SCODs as a matter of policy for a majority of Apligraf’s payment history, Congress may have


                                                 12
       However, CMS’s treatment of Apligraf as a SCOD holds little, if any, precedential value.

Although CMS acknowledges that it did, at one point, “mistakenly” pay for Apligraf as a

biological, it has never explicitly labeled Apligraf as a SCOD. Moreover, CMS asserts that

Apligraf was only “mistakenly” considered a statutory SCOD for two years — beginning in

2006, CMS began applying the SCOD payment methodology to non-SCODs as a matter of

policy. 77 Fed. Reg. 68,210, 68,383 (Nov. 15, 2012). Thus, CMS does not believe that its brief

initial mistake can create an implicit exception to the statute’s clear language.

       More importantly, this Court simply cannot review the merits of CMS’s decision here,

because CMS is not acting ultra vires. As this Circuit has previously held, “[c]ourts will

exercise their power to review alleged ultra vires agency action when an agency ‘patently

misconstrues a statute, disregards a specific and unambiguous statutory directive, or violates a

specific command of a statute.’ ” Hunter v. Fed. Energy Reg. Comm’n, 569 F. Supp. 2d 12, 16

(D.D.C. 2008) (citing to Griffith v. FLRA, 842 F. 2d 487, 493) (D.C. Cir. 1988). This Court has

already found that Plaintiff is not a SCOD under the plain terms of the statute. Thus, CMS’s

application of the unambiguous statute as written cannot be considered an ultra vires act.

   Accordingly, the Court finds that Apligraf does not meet the statutory definition of a SCOD,

and is thus governed by the general OPD grouping provisions of 42 U.S.C. §1395l (t)(2).




been ignorant of the statutory ambiguity surrounding Apligraf’s status. As a result, Congress’s
silence in this instance is hardly sufficient to overcome the clear and unambiguous terms of the
statute. See e.g. Zuber v. Allen, 396 U.S. 168, 185-86 (1969) (“Congressional inaction frequently
betokens unawareness, preoccupation, or paralysis.”); Brown v. Gardner, 513 U.S. 115, 121-22
(1994) (“As we have recently made clear, congressional silence lacks persuasive significance,
particularly where administrative regulations are inconsistent with the controlling
statute.”)(internal quotation marks omitted). This is especially true where the agency’s prior
interpretation is in fact inconsistent with the plain language of the statute. See Brown, 513 U.S. at
121-22.



                                                 13
Because CMS is not acting ultra vires, the Court’s jurisdiction to review the merits of the

agency’s final rule is precluded pursuant to 42 U.S.C. §1395l(t)(12)(A).


                                       V. CONCLUSION

       For the foregoing reasons, Defendant’s motion to dismiss is granted. As such, Plaintiff’s

motion for a preliminary injunction is denied as moot. An order consistent with this

Memorandum Opinion is separately and contemporaneously issued.


Dated: May 6, 2014                                                RUDOLPH CONTRERAS
                                                                  United States District Judge




                                                14
